Answers are grounded in this paper and cite their sources.
Pulmonary sarcoidosis progresses to fibrosing sarcoidosis with the development of respiratory failure in 5 – 20% of cases. Molecular predictors of this phenotype remain largely unstudied, necessitating transcriptome analysis of accessible patient biological material – peripheral blood mononuclear cells. The aim of this study was to evaluate the expression profile of messenger RNA (mRNA) for 14 genes involved in the regulation of cellular inflammation, immune response, cell cycle, and apoptosis in peripheral blood mononuclear cells from patients with nonfibrosing and fibrosing pulmonary sarcoidosis. Methods. A longitudinal, prospective, nonrandomized study included patients (n = 52) with pulmonary sarcoidosis (n = 28: with fibrosing (n = 5) and nonfibrosing (n = 23) variants) and apparently healthy volunteers (n = 24) as a control group. The mRNA expression level of 14 genes (TYMS, HJURP, UBE2C, BIRC5, KIF2C, CDKN1A, IRF5, IRF7, CIITA, IL1A, IL6, CXCL8, SFTPA1, SFTPB) was determined by twostage realtime RTPCR using the ΔΔCt method. ROC analysis was performed to assess the prognostic significance. Results. All patients with sarcoidosis (n = 28) had similar mRNA expression patterns for 11 genes compared with the control group (n = 24). A statistically significant decrease in expression was recorded for 3 mRNAs: CDKN1A, IRF7, and CXCL8 (IL8). CXCL8 (IL8) mRNA turned out to be the most informative in the ROC analysis: AUC – 0.668 (95% confidence interval: 0.323 – 1.000), cutoff point 0.4 (sensitivity 95%, specificity 60%). AUC for CDKN1A (0.486) and IRF7 (0.527) did not reach the threshold of acceptable prognostic significance. All p values (0.925; 0.851 and 0.248, respectively) did not reach statistical significance (p < 0.05), consistent with the pilot nature of the study. Conclusion. The level of CXCL8 (IL8) mRNA expression in peripheral blood mononuclear cells is a promising noninvasive biomarker for stratifying the risk of sarcoidosis progression, requiring further validation in large cohorts.
No takes yet. Share an insight, caveat, or question.
Arkhangelskaya et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: